Cargando…
Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies
BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427437/ https://www.ncbi.nlm.nih.gov/pubmed/36042531 http://dx.doi.org/10.1186/s41182-022-00456-x |
_version_ | 1784778902261989376 |
---|---|
author | Ghasemi, Hooman Darvishi, Niloofar Salari, Nader Hosseinian-Far, Amin Akbari, Hakimeh Mohammadi, Masoud |
author_facet | Ghasemi, Hooman Darvishi, Niloofar Salari, Nader Hosseinian-Far, Amin Akbari, Hakimeh Mohammadi, Masoud |
author_sort | Ghasemi, Hooman |
collection | PubMed |
description | BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis. METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle–Ottawa Scale checklist. Heterogeneity of the studies was measured using the I(2) test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6–40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p < 0.05). DISCUSSION: The most important strength of this study is the updated search to June 2022 and the use of all databases to increase the accuracy and sensitivity of the study. The most important limitation of this study is the lack of proper definition of polypharmacy in some studies and not mentioning the number of drugs used for patients in these studies. CONCLUSION: Polypharmacy is seen in many patients with COVID-19. Since there is no definitive cure for COVID-19, the multiplicity of drugs used to treat this disease can affect the severity of the disease and its side effects as a result of drug interactions. This highlights the importance of controlling and managing prescription drugs for patients with COVID-19. |
format | Online Article Text |
id | pubmed-9427437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94274372022-08-31 Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies Ghasemi, Hooman Darvishi, Niloofar Salari, Nader Hosseinian-Far, Amin Akbari, Hakimeh Mohammadi, Masoud Trop Med Health Research BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis. METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle–Ottawa Scale checklist. Heterogeneity of the studies was measured using the I(2) test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6–40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p < 0.05). DISCUSSION: The most important strength of this study is the updated search to June 2022 and the use of all databases to increase the accuracy and sensitivity of the study. The most important limitation of this study is the lack of proper definition of polypharmacy in some studies and not mentioning the number of drugs used for patients in these studies. CONCLUSION: Polypharmacy is seen in many patients with COVID-19. Since there is no definitive cure for COVID-19, the multiplicity of drugs used to treat this disease can affect the severity of the disease and its side effects as a result of drug interactions. This highlights the importance of controlling and managing prescription drugs for patients with COVID-19. BioMed Central 2022-08-31 /pmc/articles/PMC9427437/ /pubmed/36042531 http://dx.doi.org/10.1186/s41182-022-00456-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Ghasemi, Hooman Darvishi, Niloofar Salari, Nader Hosseinian-Far, Amin Akbari, Hakimeh Mohammadi, Masoud Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title | Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title_full | Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title_fullStr | Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title_full_unstemmed | Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title_short | Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
title_sort | global prevalence of polypharmacy among the covid-19 patients: a comprehensive systematic review and meta-analysis of observational studies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427437/ https://www.ncbi.nlm.nih.gov/pubmed/36042531 http://dx.doi.org/10.1186/s41182-022-00456-x |
work_keys_str_mv | AT ghasemihooman globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies AT darvishiniloofar globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies AT salarinader globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies AT hosseinianfaramin globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies AT akbarihakimeh globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies AT mohammadimasoud globalprevalenceofpolypharmacyamongthecovid19patientsacomprehensivesystematicreviewandmetaanalysisofobservationalstudies |